CD40 Negatively Regulates ATP-TLR4-Activated Inflammasome in Microglia

During acute brain injury and/or sterile inflammation, release of danger-associated molecular patterns (DAMPs) activates pattern recognition receptors (PRRs). Microglial toll-like receptor (TLR)-4 activated by DAMPs potentiates neuroinflammation through inflammasome-induced IL-1β and pathogenic Th17 polarization which critically influences brain injury. TLR4 activation accompanies increased CD40, a cognate costimulatory molecule, involved in microglia-mediated immune responses in the brain. During brain injury, excessive release of extracellular ATP (DAMPs) is involved in promoting the damage. However, the regulatory role of CD40 in microglia during ATP-TLR4-mediated inflammasome activation has never been explored. We report that CD40, in the absence of ATP, synergizes TLR4-induced proinflammatory cytokines but not IL-1β, suggesting that the response is independent of inflammasome. The presence of ATP during TLR4 activation leads to NLRP3 inflammasome activation and caspase-1-mediated IL-1β secretion which was inhibited during CD40 activation, accompanied with inhibition of ERK1/2 and reactive oxygen species (ROS), and elevation in p38 MAPK phosphorylation. Experiments using selective inhibitors prove indispensability of ERK 1/2 and ROS for inflammasome activation. The ATP-TLR4-primed macrophages polarize the immune response toward pathogenic Th17 cells, whereas CD40 activation mediates Th1 response. Exogenous supplementation of IFN-γ (a Th1 cytokine and CD40 inducer) results in decreased IL-1β, suggesting possible feedback loop mechanism of inflammasome inhibition, whereby IFN-γ-mediated increase in CD40 expression and activation suppress neurotoxic inflammasome activation required for Th17 response. Collectively, the findings indicate that CD40 is a novel negative regulator of ATP-TLR4-mediated inflammasome activation in microglia, thus providing a checkpoint to regulate excessive inflammasome activation and Th17 response during DAMP-mediated brain injury.     

Potential of 2, 2′-dipyridyl diselane as an adjunct to antibiotics to manage cadmium-induced antibiotic resistance in <Emphasis Type="Italic">Salmonella enterica</Emphasis> serovar Typhi Ty2 strain

One of the reasons for increased antibiotic resistance in Salmonella enterica serovar Typhi Ty2 is the influx of heavy metal ions in the sewage, from where the infection is transmitted. Therefore, curbing these selective agents could be one of the strategies to manage the emergence of multidrug resistance in the pathogen. As observed in our earlier study, the present study also confirmed the links between cadmium accumulation and antibiotic resistance in Salmonella. Therefore, the potential of a chemically-synthesised compound 2, 2′-dipyridyl diselane (DPDS) was explored to combat the metal-induced antibiotic resistance. Its metal chelating and antimicrobial properties were evidenced by fourier transform infrared spectroscopy (FTIR), field emission scanning electron microscopy (FE-SEM), and microbroth dilution method. Owing to these properties of DPDS, further, this compound was evaluated for its potential to be used in combination with conventional antibiotics. The data revealed effective synergism at much lower concentrations of both the agents. Thus, it is indicated from the study that the combination of these two agents at their lower effective doses might reduce the chances of emergence of antibiotic resistance, which can be ascribed to the multi-pronged action of the agents.     

Scanning Mutagenesis of ��-Conotoxin Vc1.1 Reveals Residues Crucial for Activity at the ��9��10 Nicotinic Acetylcholine Receptor

Vc1.1 is a disulfide-rich peptide inhibitor of nicotinic acetylcholine receptors that has stimulated considerable interest in these receptors as potential therapeutic targets for the treatment of neuropathic pain. Here we present an extensive series of mutational studies in which all residues except the conserved cysteines were mutated separately to Ala, Asp, or Lys. The effect on acetylcholine (ACh)-evoked membrane currents at the α9α10 nicotinic acetylcholine receptor (nAChR), which has been implicated as a target in the alleviation of neuropathic pain, was then observed. The analogs were characterized by NMR spectroscopy to determine the effects of mutations on structure. The structural fold was found to be preserved in all peptides except where Pro was substituted. Electrophysiological studies showed that the key residues for functional activity are Asp⁵–Arg⁷ and Asp¹¹–Ile¹⁵, because changes at these positions resulted in the loss of activity at the α9α10 nAChR. Interestingly, the S4K and N9A analogs were more potent than Vc1.1 itself. A second generation of mutants was synthesized, namely N9G, N9I, N9L, S4R, and S4K+N9A, all of which were more potent than Vc1.1 at both the rat α9α10 and the human α9/rat α10 hybrid receptor, providing a mechanistic insight into the key residues involved in eliciting the biological function of Vc1.1. The most potent analogs were also tested at the α3β2, α3β4, and α7 nAChR subtypes to determine their selectivity. All mutants tested were most selective for the α9α10 nAChR. These findings provide valuable insight into the interaction of Vc1.1 with the α9α10 nAChR subtype and will help in the further development of analogs of Vc1.1 as analgesic drugs.Marine snails belonging to the Conus genus produce a variety of neurotoxic peptides in their venom glands that they use for the capture of prey (1–3). Within this repertoire of conopeptides, those that are disulfide-rich are referred to as conotoxins. Conotoxins typically range in size from 12 to 30 amino acids, contain 4 or more Cys residues, and exhibit high potency and selectivity toward a variety of membrane receptors and ion channels (4, 5). The α-conotoxin subfamily members typically range in size from 12 to 19 amino acids, contain 2 disulfide bonds in a Cys^I–Cys^III and Cys^II–Cys^IV connectivity, and have an amidated C terminus, as depicted in Fig. 1. They interact with nicotinic acetylcholine receptors (nAChRs),⁴ of both the muscle and the neuronal type, which have been implicated in a range of neurological disorders varying from Alzheimer disease to addiction (6–8).Open in a separate windowFIGURE 1.α-Conotoxin sequences and structure of Vc1.1. a, the sequences of selected α-conotoxins relevant to this study are shown by one-letter amino acid codes. The asterisk indicates an amidated C terminus, which is a common post-translational modification found in α-conotoxins. The conserved cysteine residues are highlighted in yellow, and the Cys^I–Cys^III and Cys^II–Cys^IV disulfide connectivity is indicated by the connecting lines under the sequence. The number of residues between the cysteines define two backbone “loops,” which are used to classify α-conotoxins into subclasses. For example, RgIA has four residues in loop 1 and three residues in loop 2, making this a 4/3 loop subclass α-conotoxin. b, structural representation of Vc1.1 (PDB 2H8S), with disulfide bonds depicted in yellow. The cysteines, the loops, and the termini are labeled.The nAChRs are ligand-gated ion channels that respond to ACh, nicotine, and other competitive agonists/antagonists. They are composed of five subunits, with differing nAChR subunit composition according to the site of expression. The muscle-type nAChRs are composed of two α subunits, a β and δ subunit, and either an ϵ or a γ subunit (9–12). The neuronal forms exist either as homomeric channels composed of α subunits alone or αβ heteromeric channels. The wide variety of possible subunit combinations has led to unique subtypes with distinct pharmacological properties. This makes α-conotoxins valuable neuropharmacological tools and drug leads, because they have the ability to distinguish between different nAChR subtypes. Effectively, they are small rigid scaffolds that display amino acids on their surface to selectively target their receptors (13).Of particular interest in this study is the α-conotoxin Vc1.1, a synthetic derivative of a naturally occurring peptide from the venom of the marine cone snail, Conus victoriae. It was discovered using PCR screening of cDNA extracted from the snail venom duct (14). Fig. 1 depicts the sequences of selected α-conotoxins, including Vc1.1, which is 16 amino acids in length and displays the classic disulfide bond connectivity observed for α-conotoxins, together with a short helical segment as depicted in Fig. 1b. The conserved Cys framework of α-conotoxins defines two backbone loops, which vary in size and residue composition, and are classified by an n/m nomenclature to define subclasses of α-conotoxins. For example, Vc1.1 is a 4/7 subclass α-conotoxin, because it contains four residues in loop 1 and seven in loop 2. RgIA (15–17) is another conotoxin of interest in this study, because it is also selective for the α9α10 nAChR subtype, and has a 4/3 framework. Vc1.1 contains an amidated C terminus, a post-translational modification common to most α-conotoxins, but it is not present in RgIA. Vc1.1 lacks the post-translationally modified hydroxyproline and γ-carboxyglutamate residues present in the native peptide, vc1a, isolated from the venom duct of C. victoriae (18).Vc1.1 has been under development as a drug lead for neuropathic pain (19). When tested in rat models of neuropathic pain, Vc1.1 induced analgesia when injected intramuscularly near the site of injury (20). Initially, it was thought that α3-containing subtypes of nAChRs may be the target for Vc1.1 (21); however, it was then reported that Vc1.1 has a 100-fold higher affinity at the α9α10 nAChR subtype (22, 23). The α9α10 nAChR mediates synaptic transmission between efferent olivocochlear fibers and cochlear hair cells (24–26). The mRNA of these receptor subtypes is expressed in many different tissue types from the inner ear, dorsal root ganglion (27), skin keratinocytes (28), and lymphocytes (29) to the pituitary (26). The α10 subunit has to be expressed with the α9 subunit to form a functional receptor. In the auditory system, the α9α10 nAChR plays an important role in hair cell development, but its role in other tissues is yet to be characterized (22, 26, 30, 31).Owing to the promising antinociceptive effects of Vc1.1 in animals, its analogs are of interest as leads for the treatment of neuropathic pain (14, 20). To date, studies have predominantly focused on the α9α10 nAChR, but the very recent finding that Vc1.1 also targets the γ-aminobutyric acid, type B receptor (32) has raised interest in the molecular mode of action of Vc1.1 in analgesia. Hence there is a need to define structure-activity relationships of this peptide at several targets, including human and rat forms of the α9α10 nAChR. In particular, we were interested in analogs that maintain potency at the rat α9α10 nAChR but also show significant improvement in potency at human forms of the receptor, while maintaining selectivity over other nAChR subtypes.In this study we determined such structure-activity relationships for Vc1.1 at the α9α10 nAChR by successively mutating each non-Cys residue of Vc1.1 to either an “inert” residue (Ala), a negatively charged residue (Asp), or a positively charged residue (Lys) and observing the impact on the structure and functional activity of Vc1.1. Once the key residues had been identified, a second generation of analogs with new substitutions was synthesized and tested at the rat α9α10 nAChR. The analogs were also analyzed at the human α9/rat α10 (hα9rα10) hybrid clone, because a recent report⁵ suggested differences in the activity of Vc1.1 at the human and rat clones of the α9α10 nAChR. We also examined the effect of pH change on the structure of Vc1.1 using NMR αH chemical shift analysis. The results from this study provide valuable insight into the key residues involved in the interaction of Vc1.1 with the α9α10 nAChR subtype and have the potential to assist in the development of conotoxin analogs as drug leads for the treatment of neuropathic pain (4, 33).     

Proteome Analysis of Plasmodium falciparum Extracellular Secretory Antigens at Asexual Blood Stages Reveals a Cohort of Proteins with Possible Roles in Immune Modulation and Signaling

The highly co-evolved relationship of parasites and their hosts appears to include modulation of host immune signals, although the molecular mechanisms involved in the host-parasite interplay remain poorly understood. Characterization of these key genes and their cognate proteins related to the host-parasite interplay should lead to a better understanding of this intriguing biological phenomenon. The malaria agent Plasmodium falciparum is predicted to export a cohort of several hundred proteins to remodel the host erythrocyte. However, proteins actively exported by the asexual intracellular parasite beyond the host red blood cell membrane (before merozoite egress) have been poorly investigated so far. Here we used two complementary methodologies, two-dimensional gel electrophoresis/MS and LC-MS/MS, to examine the extracellular secreted antigens at asexual blood stages of P. falciparum. We identified 27 novel antigens exported by P. falciparum in the culture medium of which some showed clustering with highly polymorphic genes on chromosomes, suggesting that they may encode putative antigenic determinants of the parasite. Immunolocalization of four novel secreted proteins confirmed their export beyond the infected red blood cell membrane. Of these, preliminary functional characterization of two novel (Sel1 repeat-containing) parasite proteins, PfSEL1 and PfSEL2 revealed that they down-regulate expression of cell surface Notch signaling molecules in host cells. Also a novel protein kinase (PfEK) and a novel protein phosphatase (PfEP) were found to, respectively, phosphorylate/dephosphorylate parasite-specific proteins in the extracellular culture supernatant. Our study thus sheds new light on malaria parasite extracellular secreted antigens of which some may be essential for parasite development and could constitute promising new drug targets.Plasmodium falciparum is a wide spread protozoan parasite responsible for over a million deaths annually mainly among children in sub-Saharan Africa (1). Like other apicomplexan parasites such as Leishmania, Trypanosoma, and Toxoplasma, Plasmodia depend on a series of intricate and highly evolved adaptations that enable them to evade destruction by the host immune responses. These protozoan parasites have provided some of the best leads in elucidating the mechanisms to circumvent innate immunity and adaptive humoral and cellular immunity (2). Ingenious strategies to escape innate defenses include subversion of attack by humoral effector mechanisms such as complement lysis and lysis by other serum components (3), remodeling of phagosomal compartments in which they reside (4), modulation of host cell signaling pathways (5), and modification of the antigen-presenting and immunoregulatory functions of dendritic cells, which provide a crucial link with the adaptive immune response (6). Malaria parasites also predominantly use antigenic diversity and clonal antigenic variation to evade adaptive immunity of the host (7). Surface-associated and secreted parasite proteins are major players in host-parasite cross-talk and are advantageously used by the parasite to counter the host immune system. Proteins secreted by a wide range of parasitic pathogens into the host microenvironment result in symptomatic infections. For example, the excretory-secretory (ES)¹ products of the parasitic fluke Fasciola hepatica are key players in host-parasite interactions (8). Among the apicomplexans, proteomics analyses of rhoptry organelles of Toxoplasma gondii have revealed many novel constituents of host-parasite interactions (9).The identification and trafficking of Plasmodium proteins exported into the host erythrocyte have been subjects of recent detailed investigations. A number of studies have identified Plasmodium proteins that contain signature sequence motifs, the host cell targeting signal or the Plasmodium export element (PEXEL), that target these proteins into the infected erythrocytes (10, 11). Recent proteomics analyses have identified novel proteins in the raftlike membranes of the parasite and on the surface of infected erythrocytes (12, 13). P. falciparum translationally controlled tumor protein (PfTCTP), a homolog of the mammalian histamine-releasing factor, has been shown to be released into the culture supernatant from intact as well as ruptured infected RBCs and causes histamine release from human basophils and IL-8 secretion from eosinophils (14). However, the total spectrum of proteins actively exported by the asexual intracellular parasite beyond the host RBC membrane (before merozoite egress) has been poorly investigated so far.In the present study, we used two complementary methodologies, two-dimensional gel electrophoresis (2DE)/MS and LC-MS/MS to examine the cohort of extracellular secreted antigens (ESAs) at asexual blood stages of P. falciparum. Our findings reveal that malaria parasites secrete a number of effector molecules such as immunomodulators and signaling proteins that are potentially involved in host-parasite interactions. Prominent among these are proteins with Sel1 domain, a protein of the LCCL family, a novel protein kinase, and a novel protein phosphatase. Secreted-extracellular/iRBC surface localization of some of these proteins was validated by immunolocalization studies. We also characterized the functions of some of these proteins in the culture supernatant, thus providing an insight into the nature of some of the malaria parasite extracellular antigens.